Tokyo - Delayed Quote JPY

COSMOS Pharmaceutical Corporation (3349.T)

8,944.00
-96.00
(-1.06%)
At close: 3:30:00 PM GMT+9
Loading Chart for 3349.T
  • Previous Close 9,040.00
  • Open 9,000.00
  • Bid 8,930.00 x --
  • Ask 8,962.00 x --
  • Day's Range 8,890.00 - 9,065.00
  • 52 Week Range 5,777.50 - 9,574.00
  • Volume 251,300
  • Avg. Volume 408,270
  • Market Cap (intraday) 708.877B
  • Beta (5Y Monthly) 0.29
  • PE Ratio (TTM) 24.07
  • EPS (TTM) 371.54
  • Earnings Date Jul 10, 2025 - Jul 14, 2025
  • Forward Dividend & Yield 65.00 (0.72%)
  • Ex-Dividend Date May 29, 2025
  • 1y Target Est 9,075.83

COSMOS Pharmaceutical Corporation engages in the retail sale of pharmaceuticals, cosmetics, daily necessities, food, etc. in Japan. It also sells its products through online stores. The company was incorporated in 1983 and is headquartered in Fukuoka City, Japan.

www.cosmospc.co.jp

5,512

Full Time Employees

May 31

Fiscal Year Ends

Recent News: 3349.T

View More

Performance Overview: 3349.T

Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

3349.T
33.55%
Nikkei 225 (^N225)
6.51%

1-Year Return

3349.T
31.39%
Nikkei 225 (^N225)
4.23%

3-Year Return

3349.T
61.80%
Nikkei 225 (^N225)
39.49%

5-Year Return

3349.T
24.13%
Nikkei 225 (^N225)
81.48%

Compare To: 3349.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 3349.T

View More

Valuation Measures

Annual
As of 5/20/2025
  • Market Cap

    716.49B

  • Enterprise Value

    722.25B

  • Trailing P/E

    24.34

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.72

  • Price/Book (mrq)

    2.88

  • Enterprise Value/Revenue

    0.72

  • Enterprise Value/EBITDA

    17.55

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.94%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1T

  • Net Income Avi to Common (ttm)

    29.44B

  • Diluted EPS (ttm)

    371.54

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    22.77B

  • Total Debt/Equity (mrq)

    11.47%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 3349.T

View More

Company Insights: 3349.T

Research Reports: 3349.T

View More

People Also Watch